"SEER Program" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A cancer registry mandated under the National Cancer Act of 1971 to operate and maintain a population-based cancer reporting system, reporting periodically estimates of cancer incidence and mortality in the United States. The Surveillance, Epidemiology, and End Results (SEER) Program is a continuing project of the National Cancer Institute of the National Institutes of Health. Among its goals, in addition to assembling and reporting cancer statistics, are the monitoring of annual cancer incident trends and the promoting of studies designed to identify factors amenable to cancer control interventions. (From National Cancer Institute, NIH Publication No. 91-3074, October 1990)
- SEER Program
- Program, SEER
- SEER Program (National Cancer Institute (U.S.))
- Surveillance, Epidemiology, and End Results Program
Below are MeSH descriptors whose meaning is more general than "SEER Program".
Below are MeSH descriptors whose meaning is more specific than "SEER Program".
This graph shows the total number of publications written about "SEER Program" by people in this website by year, and whether "SEER Program" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
|Year||Major Topic||Minor Topic||Total|
To return to the timeline, click here.
Below are the most recent publications written about "SEER Program" by people in Profiles.
Sangaramoorthy M, Yang J, DeRouen MC, Ho C, Somsouk M, Tana MM, Thompson CA, Gibbons J, Gomez SL, Shariff-Marco S. Disparities in Hepatocellular Carcinoma Incidence in California: An Update. Cancer Epidemiol Biomarkers Prev. 2020 01; 29(1):79-87.
Riviere P, Tokeshi C, Hou J, Nalawade V, Sarkar R, Paravati AJ, Schiaffino M, Rose B, Xu R, Murphy JD. Claims-Based Approach to Predict Cause-Specific Survival in Men With Prostate Cancer. JCO Clin Cancer Inform. 2019 03; 3:1-7.
Afghahi A, Purington N, Han SS, Desai M, Pierson E, Mathur MB, Seto T, Thompson CA, Rigdon J, Telli ML, Badve SS, Curtis CN, West RB, Horst K, Gomez SL, Ford JM, Sledge GW, Kurian AW. Higher Absolute Lymphocyte Counts Predict Lower Mortality from Early-Stage Triple-Negative Breast Cancer. Clin Cancer Res. 2018 06 15; 24(12):2851-2858.
Afghahi A, Mathur M, Thompson CA, Mitani A, Rigdon J, Desai M, Yu PP, de Bruin MA, Seto T, Olson C, Kenkare P, Gomez SL, Das AK, Luft HS, Sledge GW, Sing AP, Kurian AW. Use of Gene Expression Profiling and Chemotherapy in Early-Stage Breast Cancer: A Study of Linked Electronic Medical Records, Cancer Registry Data, and Genomic Data Across Two Health Care Systems. J Oncol Pract. 2016 06; 12(6):e697-709.
Chan JK, Gardner AB, Thompson CA, Kapp DS. The use of clinical characteristics to help prevent morcellation of leiomyosarcoma: An analysis of 491 cases. Am J Obstet Gynecol. 2015 Dec; 213(6):873-4.
Roetzheim RG, Chirikos TN, Wells KJ, McCarthy EP, Ngo LH, Li D, Drews RE, Iezzoni LI. Managed care and cancer outcomes for Medicare beneficiaries with disabilities. Am J Manag Care. 2008 May; 14(5):287-96.